Press ReleasesIndustrialsSignify reports second quarter sales of EUR 1.4 billion, operational profitability of 7.8% and a free cash flow of EUR 36 million By globenewswire July 25, 2025 2 0 Signify reports second quarter sales of EUR 1.4 billion, operational profitability of 7.8% and a free cash flow of EUR 36 million Press Release Source: https://www.globenewswire.com/news-release/2025/07/25/3121588/0/en/Signify-reports-second-quarter-sales-of-EUR-1-4-billion-operational-profitability-of-7-8-and-a-free-cash-flow-of-EUR-36-million.html Tags147Amsterdam:LIGHTcashcash flowEURflownewsNL0011821392presspress releaseprofitprofitabilityquarterreleasereportssalessecond quartersource Previous articleMemo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV InfectionNext articleSohu.com to Report Second Quarter 2025 Financial Results on August 4, 2025 globenewswire FemiCore [Exclusive Report 2026] Femi Core Warning Why Thousands of Women Are Suddenly Talking About This Bladder Health Supplement June 13, 2026 There Are 16 Minerals America Produces None Of. The Government Now Calls That a National Security Threat. June 13, 2026 Glacier Breeze Portable AC: Features, Performance Claims & Consumer Feedback Evaluated in 2026 June 13, 2026 Rosen Law Firm Encourages TruBridge, Inc. Investors to Inquire About Securities Class Action Investigation – TBRG June 13, 2026 Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) June 13, 2026 Gala Night of the 28th Shanghai International Film Festival Held in Shanghai June 13, 2026 Recent News PureHealth Research Utilizes Bioavailable Cranberry and Astragalus in Premium Natural Supplements for Kidney Health SPCL Menjadi ETF A.S. Pertama dan Satu-satunya Dengan Pendedahan 2X kepada SpaceX Pada Hari IPO Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)